CliffBio
small molecule

SUCCINYLCHOLINE CHLORIDE

SUCCINYLCHOLINE CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUCCINYLCHOLINE CHLORIDE
Active ingredientSUCCINYLCHOLINE CHLORIDE
Strength100MG/5ML (20MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.